Navigation Links
Milestone Scientific to Present at the Edgewater Research Investor Conference
Date:9/26/2007

LIVINGSTON, N.J., Sept. 26 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that senior officials have been invited to present at the upcoming EdgeWater Research Fall 2007 Small/Micro Cap Conference to be held in Tucson, Arizona.

WHO: Leonard Osser, Chairman and CEO, Milestone Scientific

Joe Martin, CEO, Milestone Medical

WHEN: Wednesday, October 10, 2007 at 8:50 AM MDT

WHERE: Loews Ventana Canyon Resort

7000 North Resort Drive

Tucson, AZ 85750

EdgeWater Research Partners, LLC is an independent micro cap equities research company representing the research of David Lavigne. EdgeWater follows a number of undiscovered small and micro cap stocks through both individual research and its monthly publication, The EdgeWater Micro Monthly. EdgeWater's research is distributed to its subscriber base, and is also available on a piece by piece basis on the Company's website, http://www.edgewaterresearch.com.

About Milestone Scientific, Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) System, a computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressu
'/>"/>

SOURCE Milestone Scientific, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cancer Research: Yet Another Milestone
2. Eurand and GSK Reach Development Milestone
3. Year 2010 Envisioned to be Milestone Year for Malaria Vaccine
4. A New Milestone in Stem Cell Research
5. Scientific markers of aging described
6. A Settlement Over Stem Cell Controversy Through Scientific Research
7. A Scientific Explanation For Out Of Body Experience
8. PUFA Good For Heart: Gets The Scientific Seal
9. Forensic Phonetics – Scientific Solution for Legal Problem
10. Old Indian Advice Has A Scientific Backing Now!
11. India To Highlight Its Scientific Achievements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...stained Energy Enhancing Supplement, BOCA RATON, ...sed,nutritional supplement manufacturer, introduce...., Glyc,n Go, is the first and only chewable form...t, and the effects that it has on the,energy syste...trainers,around the globe., In clinical trials, t...
(Date:10/13/2008)...wswire/ -- NeoVista, Inc., presented,yesterday the...l,brachytherapy device on choroidal neovascular le...tina Specialist,s (ASRS) 26th Annual Meeting. The,...S., of The Methodist,Hospital, Houston, Texas, dem...y and ocular coherence tomography (OCT) in many pa...
(Date:10/13/2008)...taJobs.com and numerous newspaper affiliates have ...com . AtlantaJobs.com is the newest online job bo...bseekers in the metro Atlanta area. , ...-- AtlantaJobs.com and numerous newspaper affili...aJobs.com is the newest online job board dedicate...
(Date:10/12/2008)... Five neonatology fellows have been awarded grants...e area of follow-up care of the premature infant a...ts, which underscore MedImmune,s commitment to exp...ovide each recipient,s institution a $35,000 grant...recipients were acknowledged on Sunday, October 12...
Breaking Medicine News(10 mins):Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
...ts. Now, BT Offices and Vans will sport an anti-sm...ng is banned in the BT premises as well as in the ...tantly, this move might encourage “anti-smoking” i...n. The anti-smoking activists have seconded this ...
... improvement with Viagra could now benefit from st...ighlight the use of statins for management of endo...m erectile dysfunction. The result of this small, ...ennsylvania researchers is published in the Journa...
... Railways to take off chicken and egg related dish...n issued to all the Zonal Railways and other railw...fficial quoted that such a decision was taken upon...rest. As the disease itself is highly contagious,...
...construct a world-class cancer hospital and resear...come up at Rajarhat,// at the cost of Rs. 1.2 bill... Centre (TMC) would come up on a 10-acre plot, Wes...tacharjee and Tata Group chairman Ratan Tata said,...
Other Medicine News:Health News:Statins For Erectile Dysfunction- An Alternative To Viagra? 2
(Date:10/12/2008)...and WASHINGTON, Oct. 12 /- ...announced results from an analysis,of nearly 7,500..., which,are designed to confirm the performance of...nary Stent System in real-world practice. The,two-...t reduced clinical,restenosis in patients with dia...
(Date:10/10/2008)...Mich., Oct. 10 /- Diplomat Specialty,...s selected Diplomat,Specialty Pharmacy to be one o..., national Therapy Optimization Study for Multiple...OP MS study, is to examine the benefits of a,speci...ance, adherence and,patient outcomes. Targeted pat...
(Date:10/10/2008)..., Oct. 10 /- Inverness Medi...vider of near-patient,diagnostics, monitoring and ...n Ki-moon, the Secretary-General of the United Nat...eventeen of the world,s leading,research-based and...Inverness, together with senior officials from the...
(Date:10/10/2008)...lif., Oct. 10 /- TriReme Medical Inc.... to affix the CE (Conformite,Europeenne) marking a...y,Stent System, a unique main vessel stent system ...urcations., Representing the next generation in b...tential use in a quarter of the 2.2 million,angiop...
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 1Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 1Nventa updates progress of cervical dysplasia trial with new HspE7 1339 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 3Nventa updates progress of cervical dysplasia trial with new HspE7 1339 4Nventa updates progress of cervical dysplasia trial with new HspE7 1339 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 1FDA Panel Mulls Ban on Kids Cold Medicines 4019 2FDA Panel Mulls Ban on Kids Cold Medicines 4019 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 4
... Data presented at the 11th International Myeloma ... activity of perifosine in,combination with bortez...asone, in patients with relapsed/refractory multip... relapsed/refractory,Waldenstrom,s macroglobulinem... -- Keryx,Biopharmaceuticals, Inc. today announced...
... IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Re...entation of new,preclinical data showing their lea...A 402, is effective at protecting against,common t... This,data was presented at the annual meeting of ...n Cancer (MASSC) in St Gallen,Switzerland., Reata...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3
...ce by physicians in office based electrosurgery fo...e power settings, maintain the sterile field and d... to control the function and output of the Hyfreca...d or safety issue is detected. Cost effective alte...
...ost powerful isolated ESU on the market with 10,00...ows the surgeon to adjust power settings from the ...r Plus PC Patented Controlled Output Voltage in CU...utting through various impedance tissues with mini...
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology.
Black multi-pinhole occluder
Medicine Products: